Tripterygium wilfordii (TW) ( DrugBank: Tripterygium, Tripterygium Wilfordii )


2 diseases
IDDisease name (Link within this page)Number of trials
66IgA nephropathy1
222Primary nephrotic syndrome2

66. IgA nephropathy


Clinical trials : 255 Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00885547
(ClinicalTrials.gov)
March 200920/4/2009Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal UrinalysisProspective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis.IgA NephropathyDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNULLTerminated18 Years60 YearsBoth90N/AChina

222. Primary nephrotic syndrome


Clinical trials : 285 Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00801463
(ClinicalTrials.gov)
January 20092/12/2008Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisPrednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisProteinuria;Focal Segmental GlomerulosclerosisDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNULLCompleted18 Years60 YearsBoth67N/AChina
2NCT00518219
(ClinicalTrials.gov)
July 200716/8/2007To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)To Compare the Efficacy and Safety of TW vs Valsartan in the MNMembranous NephropathyDrug: TWNanjing University School of MedicineNULLCompleted18 Years65 YearsBoth68Phase 4China